格隆汇5月29日|据一财,波士顿科学公司已经宣布在全球范围内终止销售心脏主动脉瓣膜(TAVR)产品,原因是各国监管机构对该产品上市后新的临床试验数据更严格的要求。就在上个月,波士顿科学的TAVR瓣膜刚刚在中国举行上市会。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.